| セッション情報 |
Hepatitis C i)Hepatitis C and HCC(II)
|
| タイトル |
IF4c-5 Host Factors Determining the Efficacy of Hepatitis C Treatment
|
| 演者 |
Wan-Long Chuang（Hepatobiliary DivisionDepartment of Internal MedicineKaohsiung Medical University HospitalTaiwan） |
| 共同演者 |
|
| 抄録 |
Combination therapy wi’th pegylated interferon（PEG一工FN）and Ribavirin is the standard of care（SOC）forthe treat血ent chronic． hepatitis C（CHC）．Treating CHC with SOC may reach approxim．ately 50％of sus－tained virologic response（SVR）in genotype l C且C patients and 70 to 90％of SVR in genotype 2 CHC pa－tients in western countries． Surprisinglyusing the treatment with SOCthe SVR could be achieved to 70to 800／o in genotype 1 CHC and more than 900／o in patients with genotype 2 CHC in Asia The genotypebaseline viral load and viral kmetics （e．g． RVR and EVR） can be used as pre・dictors for response－guidedtherapy． Nonethelessthe host factorse．g． ageethnicityliver fibrosisbody weightinsulin resistancege－netic variationsmay also play important roles for the SVR in CHC patients treated with SOC． Recentlygenome－wide association studies demonstrated that SNPs near the IL28B gene were associated with SVRto treatment with SOC in CHC patients． The IL28B polymorphisms may contribute to the v辻al kineticsduring treatlnent． The Asian people have favourable皿28B polymorphisms． That may at least partly ex－plain the high eradication rate of hepatitis C by SOC in Asia． Combination therapy with direct－acting an－tivirals （DAA） and SOC can increase the SVR rates both in naive patients and treatment－experienced pa－tien／ts． Although the IL28B polymorphisms also affect the SVR of triple therapy with SOC and’ first gen－eration protease inhibitorspilot study demonstrated that potent DAAs might overcome the influence ofIL28B polymorphisms． Thusthe且CV infection could be completely eradicated in the near future in Asia． |
| 索引用語 |
|
